These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 22394995

  • 1. Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers.
    Melchior DL, Sharom FJ, Evers R, Wright GE, Chu JW, Wright SE, Chu X, Yabut J.
    J Pharmacol Toxicol Methods; 2012 Mar; 65(2):64-74. PubMed ID: 22394995
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
    Zhu HJ, Wang JS, Donovan JL, Jiang Y, Gibson BB, DeVane CL, Markowitz JS.
    Eur J Pharmacol; 2008 Jan 14; 578(2-3):148-58. PubMed ID: 17963743
    [Abstract] [Full Text] [Related]

  • 6. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
    van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, Breimer DD.
    AIDS; 2001 Mar 09; 15(4):483-91. PubMed ID: 11242145
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Derivation of a System-Independent Ki for P-glycoprotein Mediated Digoxin Transport from System-Dependent IC50 Data.
    Chaudhry A, Chung G, Lynn A, Yalvigi A, Brown C, Ellens H, O'Connor M, Lee C, Bentz J.
    Drug Metab Dispos; 2018 Mar 09; 46(3):279-290. PubMed ID: 29317410
    [Abstract] [Full Text] [Related]

  • 9. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein.
    Iwai M, Minematsu T, Li Q, Iwatsubo T, Usui T.
    Drug Metab Dispos; 2011 Dec 09; 39(12):2314-20. PubMed ID: 21918035
    [Abstract] [Full Text] [Related]

  • 10. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
    Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF.
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec 09; 364(6):551-7. PubMed ID: 11770010
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
    Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF.
    J Pharmacol Exp Ther; 2000 May 09; 293(2):376-82. PubMed ID: 10773005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.